Dashboard
Manage Tickers

ARWRARROWHEAD PHARMACEUTICALS, ...

Nasdaq arrowheadpharma.com


$ 26.89 $ -0.37 (-1.36 %)    

Tuesday, 25-Jun-2024 15:57:46 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 479.35 $ 5.42 (1.14 %)
DIA $ 391.06 $ -2.96 (-0.75 %)
SPY $ 544.78 $ 2.09 (0.39 %)
TLT $ 94.49 $ 0.16 (0.17 %)
GLD $ 214.55 $ -1.07 (-0.5 %)
$ 26.87
$ 27.17
$ 0.00 x 0
$ 0.00 x 0
$ 26.81 - $ 27.77
$ 20.67 - $ 39.83
875,564
na
3.31B
$ 1.10
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 02-06-2024 12-31-2023 10-Q
3 11-29-2023 09-30-2023 10-K
4 08-07-2023 06-30-2023 10-Q
5 05-02-2023 03-31-2023 10-Q
6 02-06-2023 12-31-2022 10-Q
7 11-28-2022 09-30-2022 10-K
8 08-04-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 02-02-2022 12-31-2021 10-Q
11 11-22-2021 09-30-2021 10-K
12 08-05-2021 06-30-2021 10-Q
13 05-04-2021 03-31-2021 10-Q
14 02-04-2021 12-31-2020 10-Q
15 11-23-2020 09-30-2020 10-K
16 08-05-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 02-05-2020 12-31-2019 10-Q
19 11-25-2019 09-30-2019 10-K
20 08-05-2019 06-30-2019 10-Q
21 05-08-2019 03-31-2019 10-Q
22 02-07-2019 12-31-2018 10-Q
23 12-11-2018 09-30-2018 10-K
24 08-07-2018 06-30-2018 10-Q
25 05-08-2018 03-31-2018 10-Q
26 02-09-2018 12-31-2017 10-Q
27 12-12-2017 09-30-2017 10-K
28 08-03-2017 06-30-2017 10-Q
29 05-03-2017 03-31-2017 10-Q
30 02-06-2017 12-31-2016 10-Q
31 12-14-2016 09-30-2016 10-K
32 08-09-2016 06-30-2016 10-Q
33 05-10-2016 03-31-2016 10-Q
34 02-09-2016 12-31-2015 10-Q
35 12-14-2015 09-30-2015 10-K
36 08-04-2015 06-30-2015 10-Q
37 05-11-2015 03-31-2015 10-Q
38 02-09-2015 12-31-2014 10-Q
39 11-25-2014 09-30-2014 10-K
40 08-12-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

arrowhead-pharmaceuticals-to-advance-investigational-plozasiran-into-phase-3-capitan-cardiovascular-outcomes-trial
Arrowhead Pharmaceuticals To Advance Inves...
06/25/2024 17:58:38

– Based on results in the Phase 2 MUIR clinical study, the Phase 3 CAPITAN trial is designed to enroll patients with mixed hype...

why-arrowhead-pharmaceuticals-arwr-stock-is-seeing-blue-skies
Why Arrowhead Pharmaceuticals (ARWR) Stock...
06/24/2024 20:24:30

Arrowhead Pharmaceuticals shares are trading higher by more than 6% during Monday's session. The company announced that it ...

arrowhead-pharmaceuticals-unveils-obesity-treatment-at-ada-conference
Arrowhead Pharmaceuticals Unveils Obesity ...
06/24/2024 11:45:22

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based...

5-biotech-stocks-with-key-catalysts-this-week-merck-intellia-verona-and-more
5 Biotech Stocks With Key Catalysts This W...
06/24/2024 08:51:47

Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach.

cantor-fitzgerald-reiterates-overweight-on-arrowhead-pharma
Cantor Fitzgerald Reiterates Overweight on...
06/20/2024 17:25:24

Cantor Fitzgerald analyst Alethia Young reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Overweight.

hc-wainwright--co-reiterates-buy-on-arrowhead-pharma-maintains-90-price-target
HC Wainwright & Co. Reiterates Buy on Arro...
06/11/2024 17:29:45

HC Wainwright & Co. analyst Patrick Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $90 pric...

goldman-sachs-initiates-coverage-on-arrowhead-pharma-with-neutral-rating-announces-price-target-of-31
Goldman Sachs Initiates Coverage On Arrowh...
06/05/2024 12:26:52

Goldman Sachs analyst Andrea Tan initiates coverage on Arrowhead Pharma (NASDAQ:ARWR) with a Neutral rating and announces Pr...

why-is-arrowhead-pharmaceuticals-stock-trading-higher-on-monday
Why Is Arrowhead Pharmaceuticals Stock Tra...
06/03/2024 17:55:23

Arrowhead Pharmaceuticals announced Phase 3 PALISADE study results showing significant triglyceride reduction in familial chylo...

hc-wainwright--co-reiterates-buy-on-arrowhead-pharma-maintains-90-price-target
HC Wainwright & Co. Reiterates Buy on Arro...
06/03/2024 17:43:06

HC Wainwright & Co. analyst Patrick Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $90 pric...

stericycle-marinemax-agios-pharmaceuticals-and-other-big-stocks-moving-higher-on-monday
Stericycle, MarineMax, Agios Pharmaceutica...
06/03/2024 14:39:44

chardan-capital-maintains-buy-on-arrowhead-pharma-maintains-60-price-target
Chardan Capital Maintains Buy on Arrowhead...
06/03/2024 13:42:36

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 price target.

arrowhead-reports-topline-results-from-pivotal-phase-3-palisade-study-of-investigational-plozasiran-says-study-successfully-met-primary-endpoint-of-lowering-triglycerides-and-met-all-key-secondary-endpoints
Arrowhead Reports Topline Results From Piv...
06/03/2024 11:36:40

Arrowhead plans to highlight recent data for its cardiometabolic pipeline at its June 25, 2024, Cardiometabolic event as part o...

arrowhead-pharmaceuticals-announced-results-from-the-phase-2b-double-blind-randomized-arches-2-study-of-investigational-zodasiran-formerly-aro-ang3-in-patients-with-mixed-hyperlipidemia
Arrowhead Pharmaceuticals Announced Result...
05/29/2024 09:42:57

arrowheads-plozasiran-shows-reductions-in-triglycerides-and-cholesterol-in-phase-2-study
Arrowhead's Plozasiran Shows Reductions in...
05/28/2024 10:06:31

Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia Business Wire - Ploza...

arrowhead-pharmaceuticals-presents-new-clinical-data-showing-aro-rage-achieves-high-level-of-gene-knockdown-in-patients-with-asthma
Arrowhead Pharmaceuticals Presents New Cli...
05/20/2024 10:02:04

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that new interim clinical data on ARO-RAGE, an investigational RN...

morgan-stanley-maintains-equal-weight-on-arrowhead-pharma-lowers-price-target-to-27
Morgan Stanley Maintains Equal-Weight on A...
05/13/2024 16:36:46

Morgan Stanley analyst Michael Ulz maintains Arrowhead Pharma (NASDAQ:ARWR) with a Equal-Weight and lowers the price target ...

hc-wainwright--co-reiterates-buy-on-arrowhead-pharma-maintains-90-price-target
HC Wainwright & Co. Reiterates Buy on Arro...
05/13/2024 15:28:07

HC Wainwright & Co. analyst Patrick Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $90 pric...

why-diodes-shares-are-trading-lower-by-around-10-here-are-other-stocks-moving-in-fridays-mid-day-session
Why Diodes Shares Are Trading Lower By Aro...
05/10/2024 16:44:44

chardan-capital-maintains-buy-on-arrowhead-pharma-maintains-60-price-target
Chardan Capital Maintains Buy on Arrowhead...
05/10/2024 14:20:55

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 price target.

arrowhead-pharma-q2-2024-gaap-eps-102-misses-012-estimate
Arrowhead Pharma Q2 2024 GAAP EPS $(1.02) ...
05/09/2024 20:09:26

Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(1.02) per share which missed the analyst consensus estimate of $(...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)